nach oben

Erschienen in:

18.08.2017 | Review

Astrocyte and Alzheimer’s disease

Erschienen in: Journal of Neurology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

The past several decades have given rise to more insights into the role of astrocytes in normal brain function and diseases. Astrocytes elicit an effect which may be neuroprotective or deleterious in the process of Alzheimer’s disease (AD). Impairments in astrocytes and their other functions, as well as physiological reactions of astrocytes to external injury, can trigger or exacerbate hyperphosphorylated tau and amyloid-beta (Aβ) pathologies, leading to the formation of both amyloid plaques and neurofibrillary tangles (NFTs), as well as neuronal dysfunction. This review addresses the involvement of astrocytes in the Aβ pathology, where the main mechanisms include the generation and clearance of Aβ, and the formation of NFTs. It is also discussed that metabolic dysfunction from astrocytes acts as an initiating factor in the pathogenesis of AD and a contributor to the onset and development of clinical presentation in AD.

Forny-Germano L, Lyra e Silva NM, Batista AF, Brito-Moreira J, Gralle M, Boehnke SE, Coe BC, Lablans A, Marques SA, Martinez AM et al (2014) Alzheimer’s disease-like pathology induced by amyloid-beta oligomers in nonhuman primates. J Neurosci 34(41):13629–13643CrossRefPubMed

Dal Pra I, Chiarini A, Pacchiana R, Gardenal E, Chakravarthy B, Whitfield JF, Armato U (2014) Calcium-sensing receptors of human astrocyte-neuron teams: amyloid-beta-driven mediators and therapeutic targets of Alzheimer’s disease. Curr Neuropharmacol 12(4):353–364CrossRef

Yoshida M (2013) Neuropathology of tauopathy. Brain Nerve 65(12):1445–1458PubMed

Shrivastava AN, Kowalewski JM, Renner M, Bousset L, Koulakoff A, Melki R, Giaume C, Triller A (2013) Beta-amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors. Glia 61(10):1673–1686CrossRefPubMed

Domene A, Cavanagh C, Page G, Bodard S, Klein C, Delarasse C, Chalon S, Krantic S (2016) Expression of phenotypic astrocyte marker is increased in a transgenic mouse model of Alzheimer’s disease versus age-matched controls: a presymptomatic stage study. Int J Alzheimers Dis 2016:5696241PubMedPubMedCentral

Choi SS, Lee SR, Lee HJ (2016) Neurorestorative role of stem cells in Alzheimer’s disease: astrocyte involvement. Curr Alzheimer Res 13(4):419–427CrossRefPubMed

Ben Haim L, Ceyzeriat K, Carrillo-de Sauvage MA, Aubry F, Auregan G, Guillermier M, Ruiz M, Petit F, Houitte D, Faivre E et al (2015) The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer’s and Huntington’s diseases. J Neurosci 35(6):2817–2829CrossRefPubMed

Lee L, Kosuri P, Arancio O (2014) Picomolar amyloid-beta peptides enhance spontaneous astrocyte calcium transients. J Alzheimers Dis 38(1):49–62PubMedPubMedCentral

Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119(1):7–35CrossRefPubMed

10.

Miller RH, Raff MC (1984) Fibrous and protoplasmic astrocytes are biochemically and developmentally distinct. J Neurosci 4(2):585–592PubMed

11.

Shtrahman E, Maruyama D, Olariu E, Fink CG, Zochowski M (2017) Understanding spatial and temporal patterning of astrocyte calcium transients via interactions between network transport and extracellular diffusion. Phys Biol 14(1):016001CrossRefPubMed

12.

Barca-Mayo O, Pons-Espinal M, Follert P, Armirotti A, Berdondini L, De Pietri Tonelli D (2017) Astrocyte deletion of Bmal1 alters daily locomotor activity and cognitive functions via GABA signalling. Nat Commun 8:14336CrossRefPubMedPubMedCentral

13.

Zheng H, Zheng Y, Wang D, Cai A, Lin Q, Zhao L, Chen M, Deng M, Ye X, Gao H (2017) Analysis of neuron-astrocyte metabolic cooperation in the brain of db/db mice with cognitive decline using 13C NMR spectroscopy. J Cereb Blood Flow Metab 37(1):332–343CrossRefPubMed

14.

Mathur R, Ince PG, Minett T, Garwood CJ, Shaw PJ, Matthews FE, Brayne C, Simpson JE, Wharton SB (2015) A reduced astrocyte response to beta-amyloid plaques in the ageing brain associates with cognitive impairment. PLoS One 10(2):e0118463CrossRefPubMedPubMedCentral

15.

Radford RA, Morsch M, Rayner SL, Cole NJ, Pountney DL, Chung RS (2015) The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci 9:414CrossRefPubMedPubMedCentral

16.

Jo WK, Law AC, Chung SK (2014) The neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogeneses of major neurocognitive disorders. Mol Psychiatry 19(2):159–167CrossRefPubMed

17.

Mancardi GL, Liwnicz BH, Mandybur TI (1983) Fibrous astrocytes in Alzheimer’s disease and senile dementia of Alzheimer’s type. Acta Neuropathol 61(1):76–80CrossRefPubMed

18.

Yamazaki M, Nakano I, Imazu O, Terashi A (1995) Paired helical filaments and straight tubules in astrocytes: an electron microscopic study in dementia of the Alzheimer type. Acta Neuropathol 90(1):31–36CrossRefPubMed

19.

Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, Arai H, Furukawa K (2016) Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem 136(2):258–261CrossRefPubMed

20.

Armato U, Chakravarthy B, Pacchiana R, Whitfield JF (2013) Alzheimer’s disease: an update of the roles of receptors, astrocytes and primary cilia (review). Int J Mol Med 31(1):3–10CrossRefPubMed

21.

Lindstrom V, Gustafsson G, Sanders LH, Howlett EH, Sigvardson J, Kasrayan A, Ingelsson M, Bergstrom J, Erlandsson A (2017) Extensive uptake of alpha-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. Mol Cell Neurosci 82:143–156CrossRefPubMed

22.

Rosenberg GA (2017) Extracellular matrix inflammation in vascular cognitive impairment and dementia. Clin Sci (Lond) 131(6):425–437CrossRef

23.

Saggu R, Schumacher T, Gerich F, Rakers C, Tai K, Delekate A, Petzold GC (2016) Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia. Acta Neuropathol Commun 4(1):76CrossRefPubMedPubMedCentral

24.

Tan CF, Piao YS, Kakita A, Yamada M, Takano H, Tanaka M, Mano A, Makino K, Nishizawa M, Wakabayashi K et al (2005) Frontotemporal dementia with co-occurrence of astrocytic plaques and tufted astrocytes, and severe degeneration of the cerebral white matter: a variant of corticobasal degeneration? Acta Neuropathol 109(3):329–338CrossRefPubMed

25.

Dvorzhak A, Vagner T, Kirmse K, Grantyn R (2016) Functional indicators of glutamate transport in single striatal astrocytes and the influence of Kir4.1 in normal and huntington mice. J Neurosci 36(18):4959–4975CrossRefPubMed

26.

Hsiao HY, Chen YC, Huang CH, Chen CC, Hsu YH, Chen HM, Chiu FL, Kuo HC, Chang C, Chern Y (2015) Aberrant astrocytes impair vascular reactivity in Huntington disease. Ann Neurol 78(2):178–192CrossRefPubMed

27.

Roberts ES, Chana G, Nguyen TB, Perera G, Landau S, Rabe-Hesketh S, Glass JD, McArthur J, Everall IP (2013) The spatial relationship between neurons and astrocytes in HIV-associated dementia. J Neurovirol 19(2):123–130CrossRefPubMed

28.

Maresca B, Spagnuolo MS, Cigliano L (2015) Haptoglobin modulates beta-amyloid uptake by U-87 MG astrocyte cell line. J Mol Neurosci 56(1):35–47CrossRefPubMed

29.

Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankowsky JL, Zheng H (2016) Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer’s disease. J Neurosci 36(2):577–589CrossRefPubMedPubMedCentral

30.

Liu RX, Huang C, Bennett DA, Li H, Wang R (2016) The characteristics of astrocyte on Abeta clearance altered in Alzheimer’s disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. Am J Transl Res 8(10):4082–4094PubMedPubMedCentral

31.

Popa-Wagner A, Buga AM, Popescu B, Muresanu D (2015) Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle. J Neural Transm (Vienna) 122(Suppl 1):S47–S54CrossRef

32.

Sharma HS, Castellani RJ, Smith MA, Sharma A (2012) The blood–brain barrier in Alzheimer’s disease: novel therapeutic targets and nanodrug delivery. Int Rev Neurobiol 102:47–90CrossRefPubMed

33.

Qosa H, LeVine H 3rd, Keller JN, Kaddoumi A (2014) Mixed oligomers and monomeric amyloid-beta disrupts endothelial cells integrity and reduces monomeric amyloid-beta transport across hCMEC/D3 cell line as an in vitro blood–brain barrier model. Biochim Biophys Acta 1842(9):1806–1815CrossRefPubMedPubMedCentral

34.

Guenette SY (2003) Astrocytes: a cellular player in Abeta clearance and degradation. Trends Mol Med 9(7):279–280CrossRefPubMed

35.

Ueno M, Chiba Y, Matsumoto K, Nakagawa T, Miyanaka H (2014) Clearance of beta-amyloid in the brain. Curr Med Chem 21(35):4085–4090CrossRefPubMed

36.

Provias J, Jeynes B (2014) The role of the blood–brain barrier in the pathogenesis of senile plaques in Alzheimer’s disease. Int J Alzheimers Dis 2014:191863PubMedPubMedCentral

37.

Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB (2017) Review: astrocytes in Alzheimer’s disease and other age-associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol 43(4):281–298CrossRefPubMed

38.

Ahmed S, Gull A, Khuroo T, Aqil M, Sultana Y (2017) Glial cell: a potential target for cellular and drug based therapy in various CNS diseases. Curr Pharm Des 23(16):2389–2399CrossRefPubMed

39.

Wakabayashi K, Miki Y (2013) Deposition and clearance of beta-amyloid in the brain. Brain Nerve 65(12):1433–1444PubMed

40.

Hu J, Lin T, Gao Y, Xu J, Jiang C, Wang G, Bu G, Xu H, Chen H, Zhang YW (2015) The resveratrol trimer miyabenol C inhibits beta-secretase activity and beta-amyloid generation. PLoS One 10(1):e0115973CrossRefPubMedPubMedCentral

41.

Yang J, Zhang R, Shi C, Mao C, Yang Z, Suo Z, Torp R, Xu Y (2017) AQP4 association with amyloid deposition and astrocyte pathology in the Tg-ArcSwe mouse model of Alzheimer’s disease. J Alzheimers Dis 57(1):157–169CrossRefPubMed

42.

Chen YL, Wang LM, Chen Y, Gao JY, Marshall C, Cai ZY, Hu G, Xiao M (2016) Changes in astrocyte functional markers and beta-amyloid metabolism-related proteins in the early stages of hypercholesterolemia. Neuroscience 316:178–191CrossRefPubMed

43.

Ourdev D, Foroutanpay BV, Wang Y, Kar S (2015) The effect of Abeta(1)–(42) oligomers on APP processing and Abeta(1)–(40) generation in cultured U-373 astrocytes. Neurodegener Dis 15(6):361–368CrossRefPubMed

44.

Hall VJ, Lindblad MM, Jakobsen JE, Gunnarsson A, Schmidt M, Rasmussen MA, Volke D, Zuchner T, Hyttel P (2015) Impaired APP activity and altered tau splicing in embryonic stem cell-derived astrocytes obtained from an APPsw transgenic minipig. Dis Model Mech 8(10):1265–1278CrossRefPubMedPubMedCentral

45.

Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach IV, Goetzl L, Schwartz JB, Miller BL (2016) Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer’s disease. FASEB J 30(11):3853–3859CrossRefPubMed

46.

Hertz L, Chen Y, Waagepetersen HS (2015) Effects of ketone bodies in Alzheimer’s disease in relation to neural hypometabolism, beta-amyloid toxicity, and astrocyte function. J Neurochem 134(1):7–20CrossRefPubMed

47.

Saha P, Biswas SC (2015) Amyloid-beta induced astrocytosis and astrocyte death: implication of FoxO₃a-Bim-caspase3 death signaling. Mol Cell Neurosci 68:203–211CrossRefPubMed

48.

Kilian JG, Hsu HW, Mata K, Wolf FW, Kitazawa M (2017) Astrocyte transport of glutamate and neuronal activity reciprocally modulate tau pathology in Drosophila. Neuroscience 348:191–200CrossRefPubMed

49.

Leyns CEG, Holtzman DM (2017) Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener 12(1):50CrossRefPubMedPubMedCentral

50.

Nilsen LH, Rae C, Ittner LM, Gotz J, Sonnewald U (2013) Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab 33(5):684–691CrossRefPubMed

51.

Thangavel R, Stolmeier D, Yang X, Anantharam P, Zaheer A (2012) Expression of glia maturation factor in neuropathological lesions of Alzheimer’s disease. Neuropathol Appl Neurobiol 38(6):572–581CrossRefPubMedPubMedCentral

52.

Reyes JF, Reynolds MR, Horowitz PM, Fu Y, Guillozet-Bongaarts AL, Berry R, Binder LI (2008) A possible link between astrocyte activation and tau nitration in Alzheimer’s disease. Neurobiol Dis 31(2):198–208CrossRefPubMedPubMedCentral

53.

DaRocha-Souto B, Scotton TC, Coma M, Serrano-Pozo A, Hashimoto T, Sereno L, Rodriguez M, Sanchez B, Hyman BT, Gomez-Isla T (2011) Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol 70(5):360–376CrossRefPubMedPubMedCentral

54.

Lace G, Ince PG, Brayne C, Savva GM, Matthews FE, de Silva R, Simpson JE, Wharton SB (2012) Mesial temporal astrocyte tau pathology in the MRC-CFAS ageing brain cohort. Dement Geriatr Cogn Disord 34(1):15–24CrossRefPubMed

55.

Wharton SB, Minett T, Drew D, Forster G, Matthews F, Brayne C, Ince PG (2016) Epidemiological pathology of Tau in the ageing brain: application of staging for neuropil threads (BrainNet Europe protocol) to the MRC cognitive function and ageing brain study. Acta Neuropathol Commun 4:11CrossRefPubMedPubMedCentral

56.

Murray ME, Przybelski SA, Lesnick TG, Liesinger AM, Spychalla A, Zhang B, Gunter JL, Parisi JE, Boeve BF, Knopman DS et al (2014) Early Alzheimer’s disease neuropathology detected by proton MR spectroscopy. J Neurosci 34(49):16247–16255CrossRefPubMedPubMedCentral

57.

Zilberter M, Ivanov A, Ziyatdinova S, Mukhtarov M, Malkov A, Alpar A, Tortoriello G, Botting CH, Fulop L, Osypov AA et al (2013) Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer’s disease. J Neurochem 125(1):157–171CrossRefPubMed

58.

Trushina E, Nemutlu E, Zhang S, Christensen T, Camp J, Mesa J, Siddiqui A, Tamura Y, Sesaki H, Wengenack TM et al (2012) Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer’s disease. PLoS One 7(2):e32737CrossRefPubMedPubMedCentral

59.

Yan LJ, Xiao M, Chen R, Cai Z (2013) Metabolic dysfunction of astrocyte: an initiating factor in beta-amyloid pathology? Aging Neurodegener 1(1):7–14PubMedPubMedCentral

60.

Mamelak M (2017) Energy and the Alzheimer brain. Neurosci Biobehav Rev 75:297–313CrossRefPubMed

61.

Bigl M, Bruckner MK, Arendt T, Bigl V, Eschrich K (1999) Activities of key glycolytic enzymes in the brains of patients with Alzheimer’s disease. J Neural Transm 106(5–6):499–511CrossRefPubMed

62.

Yun SW, Hoyer S (2000) Effects of low-level lead on glycolytic enzymes and pyruvate dehydrogenase of rat brain in vitro: relevance to sporadic Alzheimer’s disease? J Neural Transm 107(3):355–368CrossRefPubMed

63.

Allaman I, Gavillet M, Belanger M, Laroche T, Viertl D, Lashuel HA, Magistretti PJ (2010) Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci 30(9):3326–3338CrossRefPubMed

64.

Bhat R, Crowe EP, Bitto A, Moh M, Katsetos CD, Garcia FU, Johnson FB, Trojanowski JQ, Sell C, Torres C (2012) Astrocyte senescence as a component of Alzheimer’s disease. PLoS One 7(9):e45069CrossRefPubMedPubMedCentral

65.

Rocchi A, Valensin D, Aldinucci C, Giani G, Barbucci R, Gaggelli E, Kozlowski H, Valensin G (2012) NMR metabolomic investigation of astrocytes interacted with Abeta(42) or its complexes with either copper(II) or zinc(II). J Inorg Biochem 117:326–333CrossRefPubMed

66.

Rojas-Gutierrez E, Munoz-Arenas G, Trevino S, Espinosa B, Chavez R, Rojas K, Flores G, Diaz A, Guevara J (2017) Alzheimer’s disease and metabolic syndrome: a link from oxidative stress and inflammation to neurodegeneration. Synapse. doi:10.1002/syn.21990 PubMed

67.

Campos-Pena V, Toral-Rios D, Becerril-Perez F, Sanchez-Torres C, Delgado-Namorado Y, Torres-Ossorio E, Franco-Bocanegra D, Carvajal K (2017) Metabolic syndrome as a risk factor for Alzheimer’s disease: is Abeta a crucial factor in both pathologies? Antioxid Redox Signal 26(10):542–560CrossRefPubMed

68.

de la Monte SM (2017) Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs 77(1):47–65CrossRefPubMed

69.

Raider K, Ma D, Harris JL, Fuentes I, Rogers RS, Wheatley JL, Geiger PC, Yeh HW, Choi IY, Brooks WM et al (2016) A high fat diet alters metabolic and bioenergetic function in the brain: a magnetic resonance spectroscopy study. Neurochem Int 97:172–180CrossRefPubMedPubMedCentral

70.

Ellis B, Hye A, Snowden SG (2015) Metabolic modifications in human biofluids suggest the involvement of sphingolipid, antioxidant, and glutamate metabolism in Alzheimer’s disease pathogenesis. J Alzheimers Dis 46(2):313–327CrossRefPubMed

71.

Daulatzai MA (2017) Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s disease. J Neurosci Res 95(4):943–972CrossRefPubMed

72.

Iulita MF, Allard S, Richter L, Munter LM, Ducatenzeiler A, Weise C, Do Carmo S, Klein WL, Multhaup G, Cuello AC (2014) Intracellular Abeta pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun 2:61CrossRefPubMedPubMedCentral

73.

Dzamba D, Harantova L, Butenko O, Anderova M (2016) Glial cells—the key elements of Alzheimer s disease. Curr Alzheimer Res 13(8):894–911CrossRefPubMed

74.

Tarantini S, Tran CHT, Gordon GR, Ungvari Z, Csiszar A (2017) Impaired neurovascular coupling in aging and Alzheimer’s disease: contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. Exp Gerontol 94:52–58CrossRefPubMed

75.

Diniz LP, Tortelli V, Matias I, Morgado J, Paula Bergamo Araujo A, Melo HM, Seixas da Silva GS, Alves-Leon SV, de Souza JM, Ferreira ST et al (2017) Astrocyte transforming growth factor beta 1 protects synapses against Abeta oligomers in Alzheimer’s disease model. J Neurosci 37(28):6797–6809CrossRefPubMed

76.

Zheng JY, Sun J, Ji CM, Shen L, Chen ZJ, Xie P, Sun YZ, Yu RT (2017) Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer’s disease (APP/PS1) mice by inhibiting TGF-beta/Smad2/STAT3 signaling. Neurobiol Aging 54:112–132CrossRefPubMed

77.

Allaman I, Belanger M, Magistretti PJ (2011) Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci 34(2):76–87CrossRefPubMed

78.

Sailasuta N, Harris K, Tran T, Ross B (2011) Minimally invasive biomarker confirms glial activation present in Alzheimer’s disease: a preliminary study. Neuropsychiatr Dis Treat 7:495–499CrossRefPubMedPubMedCentral

79.

Morley JE, Armbrecht HJ, Farr SA, Kumar VB (2012) The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer’s disease. Biochim Biophys Acta 1822(5):650–656CrossRefPubMed

80.

Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM (2011) Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol 122(3):293–311CrossRefPubMedPubMedCentral

81.

Jhala SS, Hazell AS (2011) Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism. Neurochem Int 58(3):248–260CrossRefPubMed

Titel: Astrocyte and Alzheimer’s disease
Publikationsdatum: 18.08.2017
Erschienen in: Journal of Neurology / Ausgabe 10/2017
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-017-8593-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Astrocyte and Alzheimer’s disease

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis

Do cognition and other non-motor symptoms decline similarly among patients with Parkinson’s disease motor subtypes? Findings from a 5-year prospective study

What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients

Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment

Parkinsonian symptoms in normal pressure hydrocephalus: a population-based study

Bilateral parotid gland hemorrhage after intravenous thrombolysis for stroke treatment

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie